Seattle Startup Accipiter Biosciences Emerges with $12.7M and Big Pharma Deals for AI-Designed Proteins

Accipiter Biosciences, a Seattle-based biotech startup born from Nobel laureate David Baker’s lab at the University of Washington’s Institute for Protein Design has officially emerged from stealth with $12.7M in funding and partnerships with Pfizer and Kite Pharma. Using advanced AI tools, Accipiter Bio is pioneering a new class of de novo proteins designed to bind to multiple cellular targets at once, which could transform how complex diseases are treated.